<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02185027</url>
  </required_header>
  <id_info>
    <org_study_id>DCIC 13 18</org_study_id>
    <nct_id>NCT02185027</nct_id>
  </id_info>
  <brief_title>Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants</brief_title>
  <acronym>GIHP-NACO</acronym>
  <official_title>Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Floralis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The arrival on the market of direct oral factor Xa and factor IIa inhibitors (dabigatran
      (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis®) and others soon to come) raises novel
      questions among clinicians confronted with the emergency management of patients treated with
      these new drugs. It is likely that these new oral anticoagulants (NOACs) will eventually win
      a significant market share in the indications secondary prevention of venous thromboembolism
      and prevention of cardioembolic events in patients with nonvalvular atrial fibrillation, due
      to their net clinical benefit and their practicality of use compared with vitamin K
      antagonists (VKAs).

      However, despite the fact that NOACs reduce the incidence of intracranial bleeding by about
      half compared with VKAs, the risk remains significant; furthermore, in clinical trials, these
      drugs had little or no effect on reducing the incidence of major extracranial bleeding. In
      everyday practice, where the indication could be expanded to unselected populations and due
      to a potential for misuse, it is likely that the incidence of bleeding complications will be
      higher than that reported in clinical trials. Indeed, the numerous alerts emanating from
      regulatory agencies in various countries (US, Australia, etc.) bear witness to this, and
      should serve as a reminder that these anticoagulants have a real potential for bleeding
      complications and, in the absence of an antidote, there is no validated management strategy.

      Furthermore, as these drugs can be prescribed for months or years, patients may eventually be
      exposed to situations at high hemorrhagic risk, such as emergency surgery or invasive
      procedures, trauma, etc. Analysis of data from the RE-LY trial (dabigatran versus warfarin in
      patients with atrial fibrillation) showed that during the two years of follow-up,
      approximately 25% of the patients underwent an invasive procedure, ranging from pacemaker
      insertion to major surgery. Thus, a large proportion of patients treated with NOACs are
      concerned by this issue.

      In anticipation of a gradually increasing influx of patients in a critical situation (active
      bleeding or need to rapidly secure hemostasis before an invasive procedure), it is urgent to
      define the conduct to adopt based on the experience gained from the earliest cases. This is
      the objective of the French-speaking GIHP-NACO observatory set up by the GIHP (French Working
      Group on Perioperative Hemostasis).

      For the moment, then, the management recommendations derive from expert opinions based on
      pharmacokinetic data and on the partial correction of NOAC-induced hypocoagulability by
      various nonspecific procoagulants (non-activated or activated prothrombin complex
      concentrates, recombinant factor VIIa). These procoagulants are currently used in an
      empirical manner to control bleeding, with as many successes as failures reported in the
      literature, and their benefit-risk ratio in these patients is therefore uncertain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The management of critical situations is difficult for several reasons:

        -  First, there is significant intra- and inter-individual variability in the
           pharmacokinetics of NOACs, which is further heightened in the critical setting by drug
           interactions with other agents that interfere with P-GP (P-GLYCOPROTEIN)and cytochrome
           P4503A4 in patients who are often elderly and multi medicated, and by rapid variations
           in renal function, which is essential for elimination of NOACs.

        -  Second, biological guidance is weak: there is no clearcut therapeutic range nor any
           validated hemostatic safety cutoff, as is the case with the INR (International
           Normalized Ratio) for VKAs. Conventional coagulation tests (PT/aPTT) are poorly
           standardized and difficult to interpret. Assays to measure the serum concentrations of
           these drugs are not widespread outside of a few teaching hospitals.

        -  Third, there is a lack of clinical experience. Analyses of critical situations that
           occurred during clinical trials were done after the fact and the data collected are
           heterogeneous and incomplete. Clinical cases reported in the literature are rarely well
           documented.

      The objective of the observatory is to rapidly acquire documented and thorough feedback on
      clinical experience with these new drugs that will be able to confer a higher level of
      evidence to the management recommendations for treated patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>complications and compliance with GIHP recommendations</measure>
    <time_frame>At 1 month</time_frame>
    <description>Association between the incidence rate at 1 month post-intervention of an event among the following complications and compliance with GIHP recommendations (appended) evaluated by a composite endpoint Major cardiovascular event ( acute coronary syndrome, cardiogenic shock, stroke or TIA (Transient Ischemic Attack), extra-CNS (Central Nervous System) thromboembolic event).
Major bleeding event in the group of patients who had an emergency invasive procedure.
Continued bleeding after management (treatment, reversal) in the group of patients managed for bleeding.
Compliance with GIHP recommendations (appended) evaluated by a composite endpoint based on:
Observance of reversal strategies
Observance of the therapeutic window between the last administration and the procedure, in cases where the NOAC was stopped</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NOAC management</measure>
    <time_frame>during the perioperative period</time_frame>
    <description>All NOAC treatments will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reversal strategies description</measure>
    <time_frame>during the perioperative period</time_frame>
    <description>use or not of reversal strategies will be described</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation test results</measure>
    <time_frame>during the perioperative period</time_frame>
    <description>Coagulation test results will be recorded</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">842</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>complications and compliance with GIHP recommendations</arm_group_label>
    <description>Description at 1 month post-intervention of an potential event</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>complications and compliance with GIHP recommendations</intervention_name>
    <description>Description of complications, compliance, major bleeding events, treatments, reversal strategies.</description>
    <arm_group_label>complications and compliance with GIHP recommendations</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects managed in view of surgery or an invasive procedure, emergency or not managed and
        hospitalized for active bleeding with a long-term therapy (in the indication atrial
        fibrillation or treatment of pulmonary embolism or deep vein thrombosis) by one
        antithrombotic agent (Dabigatran, Rivaroxaban, Apixaban)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Managed in view of surgery or an invasive procedure, emergency or not

          -  Managed and hospitalized for active bleeding

          -  Long-term therapy (in the indication atrial fibrillation or treatment of pulmonary
             embolism or deep vein thrombosis) by at least one antithrombotic agent from the
             following list: DABIGATRAN ETEXILATE MESYLATE or RIVAROXABAN or APIXABAN

        Exclusion Criteria:

          -  Pregnant women

          -  Refusal to participate in the study: listed in the non-inclusion registry

          -  Antithrombotics indicated for the prevention of venous thromboembolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Albaladejo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre ALBALADEJO</last_name>
    <email>PAlbaladejo@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pauline ROMEGOUX</last_name>
    <email>PRomegoux@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Faraoni</last_name>
      <email>david.faraoni@huderf.be</email>
    </contact>
    <investigator>
      <last_name>David Faraoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Agen</name>
      <address>
        <city>Agen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Trinh-Duc</last_name>
      <email>albert.trinh-duc@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Albert Trinh-Duc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Antoinette Sevestre</last_name>
      <email>marie.sevestre@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marie-Antoinette Sevestre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Lebouc</last_name>
      <email>mlebouc@ch-annecy.fr</email>
    </contact>
    <investigator>
      <last_name>Loic Belle</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne Gautheron</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albrice Levrat</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric Heluwaert</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Samain</last_name>
      <email>e1samain@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Samain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Roullet</last_name>
      <email>stephanie.roullet@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Castres</name>
      <address>
        <city>Castres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Baptiste Rieu</last_name>
      <email>jb.rieu@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Baptiste Rieu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Chambéry</name>
      <address>
        <city>Chambery</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eléna NEAGOE</last_name>
      <email>silvia.neagoe@ch-chambery.fr</email>
    </contact>
    <investigator>
      <last_name>Eléna Neagoe</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Chastagner</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Kauffmann</last_name>
      <email>skauffmann@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Kauffmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Pascal</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Combaret</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélie Fournet-Fayard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Laure Cherprenet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélien Lebreton</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fares Moustafa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Alpes leman</name>
      <address>
        <city>Contamine-sur-Arve</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile Defournel</last_name>
      <email>cdefournel@ch-alpes-leman.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile Defournel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel De Maistre, MD</last_name>
      <email>emmanuel.demaistre@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel De Maistre</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabienne Volot</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claude Girard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Gap</name>
      <address>
        <city>GAP</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Macey</last_name>
      <email>stephmacey@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Stéphane Macey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre ALBALADEJO, MD, PhD</last_name>
      <email>PAlbaladejo@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pauline Romégoux</last_name>
      <email>PRomegoux@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sébastien Thomas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise Bouillet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles Pernod</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole Paquier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaël Marlu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yohann Dubois</last_name>
      <email>Y.DUBOIS@ghm-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Yohann Dubois</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Susen</last_name>
      <email>sophie.susen@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Susen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Trillot</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annick Genty</last_name>
      <email>annick.genty@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Yves Gueugniaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annick Genty</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Jacquin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Aubrun</last_name>
      <email>frederic.aubrun@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric Aubrun</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fédérico Bravo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Piriou</last_name>
      <email>vincent.piriou@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Piriou</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Stéphane David</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine Delaleu-Rague</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Cohen</last_name>
      <email>william.cohen@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Léone</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Morange</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Cohen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Schved</last_name>
      <email>schvedjf@aol.com</email>
    </contact>
    <investigator>
      <last_name>Jean-François Schved</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samir Jaber</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Emile Gallé - SINCAL</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien Robaux</last_name>
      <email>srobaux@sincal-cto.fr</email>
    </contact>
    <investigator>
      <last_name>Sébastien Robaux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Bouaziz</last_name>
      <email>h.bouaziz@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé Bouaziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gérard Audibert</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Heck</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Asehnoune</last_name>
      <email>Karim.asehnoune@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Karim Asehnoune</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jerome Paulus</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves Lefrant</last_name>
      <email>jean.yves.lefrant@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yves Lefrant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Niort</name>
      <address>
        <city>Niort</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Lucas</last_name>
      <email>guillaume.lucas@ch-niort.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume Lucas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Antoine Beclere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Mercier</last_name>
      <email>frederic.mercier@abc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Frederic Mercier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ismail Elalamy</last_name>
      <email>ismail.elalamy@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Ismail Elalamy</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francis Bonnet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chryssa Papageorgiou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Henri Mondor</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Matheron</last_name>
      <email>catherine.matheron@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Matheron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Longrois</last_name>
      <email>dan.longrois@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Dan Longrois</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadine Ajzenberg</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Geneviève Huisse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Marc Samama</last_name>
      <email>marc.samama@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Charles Marc Samama</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Godier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia Rosencher</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Flaujac</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Site St Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Beaussier</last_name>
      <email>marc.beaussier@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Beaussier</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Trouslard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aphp-Hegp</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Meyer</last_name>
      <email>guy.meyer@egp.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Guy Meyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier Journois</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP-Hôpital Beaujon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle De Raucourt</last_name>
      <email>emmanuelle.de-raucourt@bjn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle De Raucourt</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Josserand</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hôpital Américain</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Ihout</last_name>
      <email>Paul.IHOUT@ahparis.org</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Marret</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bicêtre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonia Blanié</last_name>
      <email>blanieodri@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dan Benhamou</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonia Blanié</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Blery</last_name>
      <email>catherine.blery@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène Beloeil</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Blery</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauren Daviet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Gueret</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annick Steib</last_name>
      <email>Annick.steib@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Annick Steib</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux du Léman</name>
      <address>
        <city>Thonon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Bouniol</last_name>
      <email>F-BOUNIOL@ch-hopitauxduleman.fr</email>
    </contact>
    <investigator>
      <last_name>François Bouniol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Sainte-Anne</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Meaudre</last_name>
      <email>eric.meaudre@club-internet.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Meaudre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Sié</last_name>
      <email>sie.p@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Sié</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Minville</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Voiron</name>
      <address>
        <city>Voiron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrille Venet</last_name>
      <email>venet_cyrille@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P; Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):382-93. doi: 10.1016/j.acvd.2013.04.009. Epub 2013 Jun 25.</citation>
    <PMID>23810130</PMID>
  </reference>
  <reference>
    <citation>Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012 Aug;108(2):217-24. doi: 10.1160/TH12-03-0179. Epub 2012 May 25. Erratum in: Thromb Haemost. 2013 Jan;109(1):169.</citation>
    <PMID>22627883</PMID>
  </reference>
  <reference>
    <citation>Sié P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, Van der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P; Working Group on Perioperative Haemostasis; French Study Group on Thrombosis and Haemostasis. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis. 2011 Dec;104(12):669-76. doi: 10.1016/j.acvd.2011.09.001. Epub 2011 Oct 29.</citation>
    <PMID>22152517</PMID>
  </reference>
  <reference>
    <citation>Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14. Erratum in: Circulation. 2012 Sep 4;126(10):e160. Heidbuchle, Hein [corrected to Heidbuchel, Hein].</citation>
    <PMID>22700854</PMID>
  </reference>
  <reference>
    <citation>Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013 May;15(5):625-51. doi: 10.1093/europace/eut083.</citation>
    <PMID>23625942</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral anticoagulants</keyword>
  <keyword>Surgery</keyword>
  <keyword>Haemorrhage</keyword>
  <keyword>Emergency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

